Between the Biotech Waves

Jul 02 2024 34 ep. 56 mins 14
Between the Biotech Waves Podcast artwork

Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.

  Science  Business
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis

Jul 02 2024 65 mins  
Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently follow

Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics

Jul 18 2023 64 mins  
Today I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS.Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pha

Episode 32: The Triplet Therapeutics story, from concept to birth, life & death.

Jul 18 2023 105 mins  
Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building

Episode 31: A Between the Biotech Waves Conversation with Tim Yu

Jul 02 2023 55 mins  
Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Juli

Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics

Jul 02 2023 45 mins  
Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involv

Episode 29: A Between the Biotech Waves conversation with Joel Marcus, Founder & Exec Chair of Alexandria Real Estate

Jun 16 2023 53 mins  
Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and their families, and through his initi

Episode 28 A Between the Biotech Waves Conversation with Rachel Meyers

Jun 16 2023 57 mins  
Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreciation not only of her as a scienti

Episode 27 A Between the Biotech Waves Conversation with Aoife Brennan, CEO of Synlogic

Apr 26 2023 66 mins  
Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare

Episode 26: A Between the Biotech Waves conversation with Drew Weissman

Feb 05 2023 57 mins  
Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career working on RNA biology and vaccine development. He, along with his colleague Katalin Kariko, have been pivotal in the development of mRNA vacc

Episode 25: A Between the Biotech Waves conversation with Rodolphe Barrangou, the Todd R Klaenhammer Distinguished Professor at NC State University.

Feb 03 2023 60 mins  
Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches including CRISPR Biotechnologies, Ancilia Biosciences, TreeCo and Intellia Therapeutics. He is one of the pioneers in CRISPR-Cas9 dating back t